FdaApplication
NDA 022030
Identifiers
- fda_app_no: NDA022030
Properties
| Property | Value |
|---|---|
| applicant_name | PFIZER INC |
| application_type | NDA |
| approval_date | 2008-10-31 |
Revenue by product
TOVIAZ
| Period | Revenue |
|---|---|
| Q4 2022 | $16.0M |
| Q3 2022 | $30.0M |
| Q2 2022 | $45.0M |
| Q1 2022 | $54.0M |
| Q4 2021 | $64.0M |
| Q3 2021 | $56.0M |
| Q2 2021 | $62.0M |
| Q1 2021 | $57.0M |
| Q4 2020 | $69.0M |
| Q3 2020 | $59.0M |
| Q2 2020 | $64.0M |
| Q1 2020 | $60.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| TOVIAZ | FESOTERODINE FUMARATE | 4MG | TABLET, EXTENDED RELEASE;ORAL |
| TOVIAZ | FESOTERODINE FUMARATE | 8MG | TABLET, EXTENDED RELEASE;ORAL |
2 products